<< Back to News

System Formulary Update
HIV Protease Inhibitors/Protease Inhibitor Boosters

Situation

The Protease Inhibitors class review and formulary standardization was approved at the August 2020 System Pharmacy and Therapeutics Committee meeting.

Background

The following medications were reviewed: atazanavir, atazanavir/cobicistat, darunavir/cobicistat, fosamprenavir, lopinavir/ritonavir, nelfinavir, ritonavir, indinavir, saquinavir, tipranavir, cobicistat, darunavir/emtricitabine/tenofovir alafenamide.

Assessment/Recommendations

Changes Effective: Tuesday July 27, 2021

System P&T voted to include the following products on the UNC Health System Drug Formulary:

• Atazanavir capsule: 300 mg
• Darunavir tablet: 600 mg, 800 mg
• Lopinavir/ritonavir tablet: 200 mg/50 mg
• Lopinavir/ritonavir oral solution: 400 mg/100 mg/5 mL
• Ritonavir tablet: 100 mg
• Cobicistat tablet: 150 mg

As a result, the following products will be removed from the inpatient drug formulary:

• Atazanavir capsule: 150 mg, 200 mg
• Fosamprenavir tablet: 700 mg
• Indinavir capsule: 400 mg
• Nelfinavir tablet: 250 mg, 625 mg
• Ritonavir oral solution: 80 mg/mL
• Saquinavir capsule: 200 mg